Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01386294
Other study ID # FACTS 001
Secondary ID
Status Completed
Phase Phase 3
First received June 28, 2011
Last updated April 16, 2015
Start date October 2011
Est. completion date August 2014

Study information

Verified date April 2015
Source CONRAD
Contact n/a
Is FDA regulated No
Health authority South Africa: Medicines Control CouncilUnited States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of the study is to assess the safety and effectiveness of intravaginal 1% tenofovir gel in preventing Human Immunodeficiency Virus (HIV-1) infection and Herpes Simplex Virus (HSV-2) infection in sexually active women.


Description:

This is a phase III, multicenter trial to assess the safety and effectiveness of 1% tenofovir gel, administered vaginally by approximately 2900 sexually active women at high risk for sexually transmitted HIV. Approximately 2600 women aged 18-30 years old will be enrolled to achieve the required number of endpoints to show an effect on HIV-1 infection, while up to 300 additional women aged 31-40 years old will be enrolled to collect more safety information in this age group.

This is an event driven study that plans to randomize seronegative women. Participants will be randomized to a 1:1 ratio to receive 1% tenofovir gel or placebo gel. Each will be asked to insert a dose of the assigned study product within 12 hours prior to a coital event and another dose as soon as possible within 12 hours after a coital event. Participants will be advised to use only two doses of gel in a 24 hour period.

All women will be evaluated for the rates of adverse events and the rate of HIV seroconversion. In addition, the study will evaluate several secondary endpoints that bear directly on potential risks and benefits of vaginal tenofovir gel use.


Recruitment information / eligibility

Status Completed
Enrollment 2059
Est. completion date August 2014
Est. primary completion date August 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria:

- Confirmed age 18-40 years (inclusive)

- Able and willing to provide written informed consent

- Able and willing to provide adequate locator information for study retention and safety purposes

- Sexually active, defined as having had vaginal intercourse at least twice in the past 30 days prior to screening

- HIV negative on two rapid tests performed by study staff within 30 days of enrolment (see algorithm in Appendix 3).

- No evidence of glycosuria

- No evidence of proteinuria greater than trace*

- No history of pathological bone fractures

- Have a negative pregnancy test

- Women currently breastfeeding may be enrolled in the study

- Agree to use a study-approved effective non-barrier form of contraception

- Agree to adhere to study visits and procedures

- Willing to use study gel as advised

- Not using or taking any of the following groups of medications:

- Nephrotoxic agents

- Drugs that slow renal excretion

- Immune system modulators

- Other antiretrovirals

Exclusion Criteria:

- History of adverse reaction to latex.

- Plans any of the following during the study period

- To travel away from the study site for more than 30 consecutive days.

- To relocate away from the study site.

- To become pregnant.

- To enrol in any other study of an investigational product or behaviour modification related to HIV prevention.

- If in the opinion of the examining clinician, is not sexually active

- Inadequate renal function (serum creatinine greater than 1.5mg/dl and creatinine clearance less than 50ml/min, as estimated using the method of Cockcroft and Gault96 )

- Grade 3 and above ALT and AST at screening or any clinical sign of liver disease ( e.g. ascites, hepatomegaly, jaundice)

- Abnormal serum phosphate levels (Grade 3 and above)

- Has a clinically apparent finding on speculum pelvic examination (observed by study staff) involving deep epithelial disruption. Otherwise eligible participants with speculum pelvic examination findings involving deep epithelial disruption may proceed with enrolment after the findings have resolved and the inclusion/exclusion are met.

- Received previously or receiving an experimental HIV vaccine

- Currently participating in another HIV prevention intervention study or participation in any other clinical trial with a biomedical intervention in the last six months

- Has current STI symptoms and/or other reproductive tract infection requiring treatment, as assessed by study staff. Otherwise eligible participants diagnosed during screening with infection(s) requiring treatment may be enrolled provided that treatment has been completed.

- Any clinical evidence of untreated cervical abnormalities

- Has any other condition that, based on the opinion of the Investigator or designee, would preclude provision of informed consent, make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Drug:
Tenofovir gel
Tenofovir gel is a clear, transparent, viscous gel at concentrations of 1% formulated in purified water with edentate disodium, citric acid, glycerin, methylparaben, propylparaben, HEC, and pH adjusted to 4-5. Tenofovir gel will be supplies in a 4 ml single use applicator containing approximately 4 grams of gel, equivalent to approximately 40mg of tenofovir.
Universal placebo gel
The placebo gel is an inert gel containing HEC as the gelling agent, purified water, sodium chloride, sorbic acid and sodium hydroxide. Each applicator contains approximately 4ml of placebo gel

Locations

Country Name City State
South Africa Desmond Tutu HIV Centre / University of Cape Town Cape Town
South Africa Perinatal HIV Research Unit / University of the Witwatersrand Diepkloof
South Africa Wits Reproductive Health and HIV Institute / University of the Witwatersrand Hillbrow
South Africa Qhakaza Mbokodo Research Clinic Ladysmith
South Africa MatCH Edendale Research Center Pietermaritzburg Kwa-Zulu NAtal
South Africa Medunsa Clinical Research Unit / Ga-Ra Pretoria
South Africa The Aurum Institute (Rustenburg) Rustenburg
South Africa Setshaba Research Centre Soshanguve
South Africa The Aurum Institute, Tembisa Hospital Tembisa

Sponsors (3)

Lead Sponsor Collaborator
CONRAD Follow-on African Consortium for Tenofovir Studies (FACTS), United States Agency for International Development (USAID)

Country where clinical trial is conducted

South Africa, 

Outcome

Type Measure Description Time frame Safety issue
Primary Effectiveness Incidence of HIV-1 infection: HIV incidence will be determine by detection of HIV antibodies using two HIV rapid tests (of which one will be FDA approved) according to algorithm in protocol. One of the rapid tests will detect both HIV-1 and HIV-2; the other will be specific for HIV-1. All endpoints will be reviewed by an expert committee (the Endpoint Adjudication Committee). In carrying out this review, the Committee will use guidelines prepared by the protocol committee for this purpose and recorded in the Manual of Procedures 30 months No
Primary Safety Grade 2, 3, and 4 clinical and laboratory adverse events as defined by the DAIDS toxicity table 30 months Yes
Secondary Incidence of HSV-2 infection HSV-2 status will be established at enrollment according to a testing algorithm in the protocol. At product discontinuation samples of all those that were HSV-2 seronegative at enrollment will be tested. To identify and confirm incident HSV-2 infections and the timing of these infections, blood samples that were stored will be tested to determine the earliest equivocal or positive result. These samples will be then be tested by HSV Western blot. Samples positive on HSV Western blot will be deemed to be incident HSV-2 infections. 30 months No
Secondary Pregnancy Incidence of pregnancy loss, prematurity, low birth weight, and major and minor congenital anomalies will be determined 30 months No
Secondary Gel and condom use 30 months No
Secondary HIV-1 incidence after product withdrawal HIV testing will be conducted 3 months after product discontinuation and if HIV positive, the last stored sample will be tested to ascertain timing of infection and viral tenofovir resistance testing will be performed 3 months after product withdrawal No
See also
  Status Clinical Trial Phase
Completed NCT03411577 - Development and Testing of a Jamaican Mother-daughter HIV Risk-reduction Program N/A
Active, not recruiting NCT03112369 - Preventing HIV Among Native Americans Through the Treatment PTSD & Substance Use N/A
Not yet recruiting NCT03642314 - HIV Self-testing in Implementation PrEP Study N/A
Completed NCT01810315 - Influence of Reproductive Cycle and Menopause on HIV-1 Infection and TFV Gel Activity Phase 1
Completed NCT00984971 - Rectal Microbicide Safety and Acceptability Trial of Topically Applied Tenofovir Compared With Oral Tablet Phase 1
Completed NCT00142935 - Effectiveness of Opiate Replacement Therapy Administered Prior to Release From a Correctional Facility - 1 N/A
Active, not recruiting NCT03255915 - PrEP-Pod-IVR (TDF-FTC/Placebo IVR 28 Day Crossover Study) Early Phase 1
Completed NCT05037513 - Integrated PrEP Interventions for People Who Inject Drugs in Rural Kentucky N/A
Recruiting NCT05087680 - An Acceptance Based PrEP Intervention to Engage Young Black MSM in the South N/A
Recruiting NCT05804461 - Optimizing Pre-Exposure Prophylaxis (PrEP) Among Latino Men Who Have Sex With Men (MSM) in Puerto Rico N/A
Completed NCT03148171 - Project WERK (Wellness Encouragement Respect Kinship) N/A
Completed NCT04791007 - OB-002H Gel Administered Vaginally and Rectally in HIV-1 Seronegative Adults Early Phase 1
Recruiting NCT05412433 - Clinic-based HIV Identification and Prevention Project Using Electronic Resources N/A
Active, not recruiting NCT03977181 - The Community PrEP Study to Assess the Acceptance of PrEP Delivered Through CBCT Platforms N/A
Recruiting NCT05165745 - Stick2PrEP Cisgender Women and Trans Individuals N/A
Completed NCT03719053 - Single Dose Truvada Study Phase 1
Recruiting NCT03856580 - Long-acting Biomedical HIV Prevention in Transgender Women N/A
Completed NCT02750540 - Optimization of a Tenofovir Enema for HIV Prevention Phase 1
Completed NCT00993811 - The Shang Ring: A Novel Male Circumcision Device for HIV Prevention Phase 1
Completed NCT01028157 - S.T.A.R.S.: Sistas Talking About Real Solutions Phase 1